Allspring Global Investments Holdings LLC Sells 839 Shares of Medpace Holdings, Inc. $MEDP

Allspring Global Investments Holdings LLC trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 23.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,814 shares of the company’s stock after selling 839 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Medpace were worth $1,377,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. BOKF NA lifted its holdings in shares of Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after acquiring an additional 20 shares during the period. Valeo Financial Advisors LLC increased its stake in Medpace by 5.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after acquiring an additional 21 shares during the last quarter. UMB Bank n.a. raised its position in Medpace by 5.6% during the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after purchasing an additional 24 shares in the last quarter. Schulhoff & Co. Inc. raised its position in Medpace by 1.1% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after purchasing an additional 25 shares in the last quarter. Finally, Berkeley Inc lifted its stake in Medpace by 1.0% during the fourth quarter. Berkeley Inc now owns 2,694 shares of the company’s stock worth $1,513,000 after purchasing an additional 27 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
• Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
• Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
• Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $601.38 on Monday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The firm has a market cap of $16.78 billion, a PE ratio of 35.25, a price-to-earnings-growth ratio of 2.68 and a beta of 1.15. The firm’s fifty day moving average is $492.09 and its 200-day moving average is $493.84.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the business posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts forecast that Medpace Holdings, Inc. will post 17.59 EPS for the current year.

Insider Activity at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 20.50% of the company’s stock.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of research analyst reports. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and raised their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. BMO Capital Markets boosted their price target on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday. TD Cowen upped their price objective on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Finally, Leerink Partners set a $620.00 target price on Medpace in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $560.92.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.